NEW YORK (GenomeWeb News) – Tissue supply firm Asterand today said that its BioSeek subsidiary will provide its BioMap predictive human disease models to Cellzome for use in its inflammatory disease drug discovery projects.
The BioMap platform will be used to predict possible human clinical responses to small molecules identified by Cellzome using its own Kinobeads and Episphere screening and profiling technologies. The agreement is for two years.
"The BioMap platform will allow us to receive early insight into the human pharmacological and toxicological properties of our small molecules, enabling us to develop safer and more effective treatments for inflammation," Oliver Rausch, VP of Biology at Cambridge, UK-based Cellzome, said in a statement.
Financial and other terms of the agreement were not disclosed.